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Abstract
Purpose—Severe skeletal muscle (SM) loss (sarcopenia), is associated with poor cancer 
outcomes including reduced survival and increased toxicity. This study investigates SM measures 
in metastatic breast cancer (MBC) patients receiving first line taxane-based chemotherapy and 
evaluates associations with treatment toxicity and other outcomes.
Experimental Design—Using computerized tomography (CT) images taken for the evaluation 
of disease burden, skeletal muscle area (SMA) and density (SMD) were measured at the 3rd 
lumbar vertebrae. Sarcopenia was defined as Skeletal Muscle Index (SMI=SMA/height2) ≤41. 
Skeletal Muscle Gauge (SMG) was created by multiplying SMI x SMD. Fisher’s exact tests, t-
tests, the Kaplan-Meier method, and Cox regression modeling were used.
Results—MBC patients (N=40), median age 55 (rang 34–80), 58% sarcopenic, median SMG 
1296 AU (SD 522). Grade 3–4 toxicity was found in 57% of sarcopenic vs 18% of non-sarcopenic 
patients (p=0.02). Toxicity-related hospitalizations were also higher in sarcopenic patients (39% vs 
0%, p=0.005) as were any adverse events -- defined as any grade 3–4 toxicities, hospitalizations, 
dose reductions, or dose delay -- (74% vs 35%, p=0.02). Low SMG was associated with grade 3–4 
toxicity (p=0.04), hospitalization (p=0.01) and time to treatment failure (for progression or 
toxicity) (p=0.03). Low SMG had a borderline significant association with any adverse event 
(p=0.06) and overall survival (p=0.07).
Conclusions—SM measures are associated with toxicity outcomes and survival in MBC 
patients receiving first line taxane-based chemotherapy. Further studies are needed to explore how 
routinely obtained CT scans can be used to individualize dosing and improve treatment planning.
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Introduction
With over 1.5 million new cases per year, breast cancer is the most common cancer and 
leading cause of cancer mortality in women worldwide (1). In the U.S. in 2016, there will be 
an estimated 246,660 new cases of breast cancer and 40,450 breast cancer deaths, most of 
them due to metastatic disease (2). Six to ten percent of new metastatic breast cancer (MBC) 
cases are diagnosed as “de novo” Stage IV and an estimated 20–30% of all existing breast 
cancer cases will have metastatic recurrence (3). When distant metastasis are diagnosed, 
breast cancer is incurable with a median survival of 2 to 3 years (4). Chemotherapy is an 
essential component of treatment for MBC and toxicity prediction is an important challenge 
in oncology practice.
The term sarcopenia was described by Baumgartner et al to describe age-related loss of 
muscle mass in older adults (5). He developed an index of relative muscle mass calculated as 
the appendicular skeletal muscle mass, measured by dual-energy x-ray absorptiometry 
(DEXA). More recently, sarcopenia research in oncology has focused on technology that 
uses widely available computed tomographic (CT) imaging (6) that is used for staging, 
surveillance, and assessing tumor response in patients with cancer.
Sarcopenia is a commonly observed in patients with advanced cancer. In a recent meta-
analysis, 19–74% of patients with advanced solid tumors were sarcopenic, and the presence 
of sarcopenia was correlated with poor overall survival (OS) (Hazzard ratio (HR)=1.44, 
p<0.001)(6). Prado et al found a significant association between sarcopenia and capecitabine 
toxicity in MBC patients. Pre-existing sarcopenia was associated with toxicity in 50% of 
patients compared to 20% who were non sarcopenic (p=0.03); time to tumor progression 
(TTP) was also shorter for sarcopenic vs non-sarcopenic patients (101 versus 173 days, 
respectively; p=0.05) and had an independent effect on TTP in multivariate model (HR= 2.6; 
p=0.01) (7). In an Asian study of early breast cancer patients, which examined the 
association between body composition and toxicity from doxorubicin, it was shown that 
higher increased visceral fat was significantly associated with grade 4 leukopenia (p=0.014)
(8). These findings suggest that different body composition measures may be a predictor of 
chemotherapy toxicity.
To further explore the potential role of sarcopenia as a predictor of toxicity and other adverse 
clinical outcomes we studied patients with metastatic breast cancer who had first line 
chemotherapy with taxanes and who had baseline CT that allowed for measurement of 
muscle mass. We chose taxanes as these are among the most widely used and effective 
agents in this setting (9, 10). The purpose of this study was to investigate if skeletal muscle 
and body composition measures - body surface area (BSA), body mass index (BMI), lean 
body mass (LBM), skeletal muscle density (SMD), and a novel measure of skeletal muscle 
gauge (SMG) were associated with chemotherapy toxicity, hospitalizations, dose delays or 
reductions, time to treatment failure, and overall survival.
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Patients and Methods
Participants
To be eligible for this study, patients needed to be female, age 21 or older, and receiving 
chemotherapy for MBC at the University of North Carolina (UNC) Cancer Hospital. Patients 
had to be undergoing the following commonly-used first line taxane-containing 
chemotherapy regimens: paclitaxel, docetaxel, or nab-paclitaxel. Patients with any 
histological type, grade, hormone receptor status, or HER-2 status were eligible. Patients 
also had to have a CT scan of the abdomen dating no more than 45 days prior to 
chemotherapy initiation with digital images available for muscle mass assessment and 
complete medical records at UNC. Eligible patients were identified through a review of 
patients in the IRB-approved UNC Metastatic Breast Cancer Clinical Database. There was 
no direct contact with patients, as all data were collected through registry and electronic 
medical records. The study was approved by the UNC Institutional Review Board.
Toxicity grading and measures
Toxicity grades 3–5 according to National Cancer Institute Common Toxicity Criteria for 
adverse events (11) (NCI- CTCAE) (Version 4.03) were captured from the electronic 
medical record (EMR). We specifically focused our chart review on hematologic toxicity 
(neutropenia, thrombocytopenia, anemia), febrile neutropenia, white blood cell growth factor 
(G-CSF) usage, neurotoxicity, gastrointestinal toxicity (stomatitis, diarrhea, vomiting), dose 
reductions and treatment delays, hospitalizations due to chemotherapy toxicity, and death. If 
there was any uncertainty concerning hospitalization due to treatment toxicity, a second 
medical oncologist reviewed the charts and the patient’s cause of hospitalization was 
adjudicated by consensus. A composite variable of “any adverse event” was defined as any 
hospitalization, grade 3–4 toxicity, dose reductions, or dose delay. Time to treatment failure 
(TTF) was defined as days from start to end of chemotherapy whether stopped for either 
toxicity or tumor progression. OS was defined as the time in years from chemotherapy 
initiation to either death or last date of contact.
Other measures
In addition to toxicity data, we also collected age at diagnosis of metastasis, disease free 
interval, hormone receptor (HR) subtype, metastatic sites, whether a biologic agent was used 
with chemotherapy, the type of taxane chemotherapy, BSA, BMI, and prior hormonal 
therapy (if used).
BMI was calculated using the following formula: BMI = weight (kg)/height2 (m2). 
Classification of obese referred to patients with BMI ≥30.0 kg/m2. BSA was calculated 
using: .
CT-based body composition measures
Abdominal CT images were acquired from the UNC Picture Archiving and Communication 
System office and analyses were conducted with the guidance of a faculty radiologist. CT 
images were examined using Impax radiological software (AGFA-version 6, Morstel, 
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Belgium) and transverse sections at the level of L3 were extracted for our analyses. L3 
lumbar segments were processed using automated image segmentation software,(12, 13) The 
software recognizes muscle tissue based on density threshold between −29 and +150 HU, 
while using a priori information about the L3 muscle shape to avoid mislabeling parts of the 
neighboring organs that also have HU values in the −29 +150 range. The program provides a 
highly accurate, unbiased estimation of the cross-sectional lean tissue area and skeletal 
muscle area. Skeletal muscle index (SMI) was calculated using the following formula -- (L3-
muscle area-cm2)/(patient height-m2) (14). An SMI of 41 or less was considered sarcopenic 
based on previously derived optimal stratification statistics relating SMI to increased 
mortality in a large population of patients with colorectal and lung cancer (14). Estimation 
of LBM was calculated using the formula (7) (LBM (kg) = [(L3 Muscle measured by CT 
(cm2) × 0.3) + 6.06]).
Mean SMD was derived by averaging Hounsfield Units (HU) of skeletal muscle at the L3 
vertebrae. The attenuation of skeletal muscle is used as a non-invasive radiological technique 
to indirectly assess muscle fat content. The density of skeletal muscle is inversely related to 
muscle fat content (15). Since SMI and SMD are each significantly associated with outcome 
(6, 16, 17), we explored whether combining the two skeletal muscle measures together 
resulted in stronger correlations with outcomes. To integrate both skeletal muscle quantity 
(SMI) and skeletal muscle density (SMD), we used the “skeletal muscle gauge” (SMG) by 
multiplying SMI x SMD first presented by Weinberg et al. The actual units for SMG are: 
(cm^2 tissue * average HU)/(m^2 height) for simplicity we chose to represent them as 
arbitrary units (AU)(18) (see Figure 1).
Statistical analysis
Fisher’s exact and two group t-tests were used evaluate associations between body 
composition measures and toxicity. The Kaplan-Meier method was used to estimate median 
times, and univariable Cox regression modeling was used to estimate hazard ratios and 
compare TTF and OS. A p-value of <= .05 was considered statistically significant. To 
illustrate, the Kaplan Meier curve was created using the median SMG as a cutoff. Analyses 
were conducted using SAS statistical software version 9.4 (Cary, NC).
Results
Study population
Forty patients were identified who met eligibility criteria (see Supplementary Figure 1). 
Patients, treatment and toxicity characteristics described in Table 1. The median age was 55 
years (range 34 – 80) and the mean disease free interval was 3.8 years. All patients were 
chemotherapy-free for at least 6 months since the adjuvant chemotherapy. Metastatic 
diagnosis period was 2003–2015. Median time from CT scan to chemotherapy initiation was 
20 days [range 2–36 days prior]. Median length of follow up for the survivors was 1.9 years. 
Patient characteristics are shown in Table 1. Chemotherapy regimens are shown in table 1 
and included: paclitaxel (N=31 weekly schedule, 26 patients received 80 mg/m2, 4 patients 
received 90 mg/m2 on clinical trial, and one patient was dose reduced 20% (64 mg/m2) 
because of liver function test (LFT) abnormality), docetaxel (N=4, two received 75 mg/m2, 
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one 60 mg/m2 (dose reduced due to high LFTs) and one 100 mg/m2 at first dose-every 3 
weeks), and nab-paclitaxel (N=5, one patient received 260 mg/m2, one patient received 25 % 
dose reduction (195 mg/m2) from first dose because of her age and performance status-every 
3 weeks, two received 100 mg/m2 weekly dose, and one received 175 mg/m2 every two 
weeks on clinical trial).
Fifteen patients (37.5%) received biological therapy in addition to a taxane (trastuzumab 
(N=11) and pertuzumab/trastuzumab (N=4)). Ten patients (25%) received the anti-
angiogenesis inhibitor bevacizumab with a taxane. Of the 40 eligible patients, 58% were 
identified as sarcopenic (Table 1 for baseline body composition metrics). No grade 5 (death) 
toxicity was recorded.
Body composition as a predictor of grade 3–4 toxicity
Sixteen patients (40%) developed grade 3–4 toxicity during cycles 1–3. Of note, none of the 
toxicities recorded are likely due to the biologic agent used with the corresponding taxane. 
There was one patient with diarrhea receiving trastuzumab but none of the four pertuzumab 
treated patients had grade 3 or 4 diarrhea. Sarcopenic patients experienced significantly 
more grade 3–4 toxicity compared to non-sarcopenic patients (figure 2A, 57% vs 18%, 
p=0.02). Patients who had grade 3–4 toxicity during cycles 1–3 had significantly lower SMG 
than those who did not (figure 2B, mean 1046 vs 1385, p=0.04) and also lower SMD (26.6 v 
31.9, p=0.010). BMI, BSA, and estimated lean body mass (LBM), were not associated with 
cycle 1–3 toxicity.
Body composition as a predictor of hospitalizations
Nine patients were hospitalized due to treatment-related toxicity and all were sarcopenic. 
Hospitalizations were significantly associated with low lean body mass (34.7 vs 40.6, 
p=0.03), low SMD (23.3 vs 31.7, p=0.03), and low SMG (862 vs 1362, p=0.01).
Body composition as a predictor of any adverse event
Adverse events (hospitalization, grade 3–4 toxicity, dose reductions, or delay) occurred in 23 
patients, of which 17 (74%) were sarcopenic. Sarcopenia was significantly associated with 
any adverse event (74% sarcopenic vs 35% not sarcopenic, p=0.02). Lower SMG had a 
borderline significant association with any adverse event (1115 vs 1431, p=0.06). All 
toxicity events summarized in table 2.
Body composition as a predictor of time to treatment failure and overall survival
Median TTF for the entire sample was 6.5 months (95% CI: 3.4 – 9.2 months), with no 
significant difference between sarcopenic and non-sarcopenic patients (median 6.2 vs 9.2 
months, p=0.18; see table 3). BMI, BSA, LBM, and SMD were also not associated with 
time to treatment failure. However, SMG was significant and for each 100 unit increase, a 
patient’s risk of treatment failure decreased by 9% (Figure 3A, HR=0.91, 95% CI 0.84–0.99, 
p=0.03). Median OS for the entire sample was 32.3 months (95% CI: 23.4–40.3 months), 
with borderline significant difference between sarcopenic and non-sarcopenic patients 
(median 30 vs 40.3 months, p=0.07). BMI, BSA, LBM, and SMD were not associated with 
differences in OS. Low SMG had a borderline significant association with shorter survival 
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(Figure 3B) and for each 100 unit increase a patient’s risk of death decreased by 7% 
(HR=0.93, 95% CI 0.87–1.00, p=0.07).
Discussion
This study found that body composition measures varied widely in women with MBC 
receiving first line taxane-based chemotherapy regimens, and that body composition and 
skeletal muscle measures could have important implications for treatment decisions. 
Sarcopenic patients had 3 times more grade 3–4 toxicity and twice the number of adverse 
events. Of note all treatment related hospitalizations (N=9) were in sarcopenic patients. 
SMG, a novel measure of body composition, was significantly associated with grade 3–4 
toxicity, hospitalizations related to treatment toxicity, and TTF. SMG was also borderline 
significant predictor of adverse events and overall survival. LBM was significantly 
associated with hospitalizations while BMI and BSA were not predictive of toxicity. In our 
sample of patients none were underweight [BMI<=18.5] indicating that sarcopenia and 
SMG are independent of BMI. Of note, the number of hospitalizations in our study was 
higher than excepted (19). Most of the data regarding hospitalizations from taxanes toxicity 
come from randomized trials with strict eligibility and performance status criteria. These 
patients are not representative of those seen in general oncology practice.
Our results are in line with findings reported in other studies, such as Prado et al, showing 
higher toxicity and shorter time to progression in sarcopenic MBC patients receiving 
capecitabine who had failed anthracycline and/or taxane treatment (7). Unlike in our study 
where we focused on more severe toxicity grades, Prado and colleagues included grade 2 
toxicity in her outcome assessments. Similarly, Tamandl et al showed that low skeletal 
muscle attenuation was associated with impaired OS (HR =1.91, 95 % CI 1.12–3.28, 
p=0.019) in gastro-esophageal cancer (16) and a Dutch study in metastatic colorectal cancer 
also found similar results (HR=2.38 95% CI- 1.16–4.87 p=0.018)(17). Our study provides an 
innovative contribution to the literature by taking into account not only the quantity of the 
muscle (SMI) but also the muscle composition “quality” (SMD) and using a new novel body 
composition parameter that combines the two -- SMG. We believe that this measure may 
prove to be the most important, and as it combines two measures of muscle that have been 
shown to be independent predictors of outcomes in other studies.
There is growing interest in exploring the relationship between body composition, toxicity, 
and treatment outcomes in early (20–22) and advanced (7, 23–27) cancer patients. With 
simplified and standardized image analysis of CT images, these measures could be easily 
performed by radiologist using existing CT images obtained as part of routine care in both 
the academic and community setting. Sarcopenia and other body composition measures may 
provide independent information for assessing treatment risks and guiding disease 
management with potential dosing implications (28, 29). Typically, physicians dose patients 
based on body surface area (30), but recently there is a growing evidence that LBM is better 
correlated with drug clearance pharmacokinetics than BSA (31). The desire to select 
chemotherapy doses that maximize the therapeutic index has existed for a long time (32), but 
until recently no simple, readily available tools existed to do so. Our research and that of 
others suggests that sarcopenia as measured from routine CT images obtained as part of 
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staging or to evaluate treatment response might perform this role (21, 33). Using body 
composition measurements to individualize dosing could represent a dramatic step forward 
into the personalized medicine era
Understanding the importance of sarcopenia and body composition in patients with cancer 
also highlights the need for timely interventions to increase or prevent further loss of muscle 
mass during treatment and in survivorship. Intervention research to date has focused on 
exercise (34–36), vitamin D (37), and omega-3 fatty acid dietary supplementation (38). 
Other new therapeutic approaches including melanocortin-4 receptor antagonists (39) and 
IL-6 antagonism (40) are also under investigation. Recently, a randomized controlled trial in 
lung cancer that compared anamorelin a novel ghrelin-receptor agonist to placebo showed 
significant LBM gain in the intervention arm (41). Further research on the impact of these 
interventions on toxicity and efficacy outcomes and how to incorporate them into oncology 
practice is needed.
Our study is not without limitations. First we had a small sample size, which likely limited 
our statistical power to detect significant differences in some of the body composition 
measurements and outcomes. Second, many of our patients received concurrent treatment 
with biologic agents (trastuzumab and bevacizumab). This may have affected our results, 
since biologics have toxicity profiles that differ from chemotherapy. However, the toxicities 
reported in study are highly unlikely to be due to the addition of biologic therapy as noted in 
the results section above. Another limitation is combining different taxane regimens that -- 
although they have a similar mechanism of action -- have different pharmacokinetics and 
different toxicity profiles. Given this concern, we performed a sensitivity analysis of patients 
that received paclitaxel only (N=31). We found that sarcopenia remained a significant 
predictor for grade 3–4 toxicity (p=0.05) and any adverse event (p=0.03), and was borderline 
for hospitalizations (6 patients that received paclitaxel were hospitalized due to toxicity and 
all were sarcopenic, p=0.07). SMG became borderline significant with hospitalization (SMG 
1362 vs 908 AU, p=0.06), any adverse event (1448 vs 1130 AU, p=0.10), and grade 3–4 
toxicity (1388 vs 1067 AU, p=0.11). Due to differences in pharmacokinetics and toxicity 
profiles of taxanes, we encourage future studies to explore each of these drugs separately.
To the best of our knowledge this is the first study that examines the effect of body 
composition measures in metastatic breast cancer treated with taxanes. Our results show that 
body composition is correlated with cancer and toxicity outcomes and suggest that patients 
with low muscle mass or LBM have more treatment related toxicity, while BSA has no 
correlation with toxicities. Using existing imaging and readily available software, skeletal 
muscle mass assessments could be incorporated into the clinical setting. Further research 
using body composition assessments to develop novel dosing strategies as well as targeting 
effective interventions is necessary in patients with cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF TRANSLATIONAL RELEVANCE
This paper contains a number of novel concepts regarding chemotherapy toxicity and 
represents the first study of the impact of skeletal muscle measures in patients with 
metastatic breast cancer receiving taxane chemotherapy. Muscle measures have an 
emerging role in predicting treatment toxicity and survival in patients with cancer. Our 
results shows that sarcopenic (low muscle mass) patients have more treatment related 
adverse outcomes such as grade 3–4 CTCAE toxicities, hospitalizations, and other 
adverse events. Furthermore, our work is the first to demonstrate the innovative 
combination of muscle mass (quantity) and radiodensity (quality) as a predictor to 
chemotherapy outcome. Our results suggest that muscle measurements obtained from 
computed tomography (CT) images performed for routine oncologic care could be used 
to individualize chemotherapy dosing better than body surface area.
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Figure 1. 
Three examples of body composition, all BMI = 32
A: normal SMI and high SMG; B: sarcopenic and low SMG; C: normal SMI and low SMG;
Abbreviations: AU – Arbitrary Units; HU - Hounsfield Units; SMI - Skeletal Muscle Index; 
SMG - Skeletal Muscle gauge
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Figure 2. 
Skeletal muscle measures and adverse outcomes
A –Sarcopenia and adverse outcomes; B –Skeletal muscle gauge and adverse outcomes
† Grade 3–4 toxicity by CTCAE(11) in cycles 1–3 of chemotherapy; *p =0.005; **p =0.02
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Figure 3. 
Skeletal muscle measures and time to event
A- Skeletal muscle gauge and time to treatment failure; B- Skeletal muscle gauge and 
overall survival
Time to treatment failure was defined as days from start to end of chemotherapy whether 
stopped for either toxicity or tumor progression.
The p-value for SMG as a continuous variable is 0.03 for time to treatment failure and 0.07 
for overall survival.
Abbreviations: SMG- Skeletal Mass Gauge
Shachar et al. Page 14
Clin Cancer Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Shachar et al. Page 15
Table 1
Patients characteristics, body composition measures, and toxicity events (N=40)
N/mean (SD) %
Age at metastatic diagnosis years 56 (11.7)
Age < 65 years 33 83
Disease free interval (years) 3.8 (5.2)
Subtype
HR positive/HER2 negative 15 38
HER2 positive 14 36
HR negative/HER2 negative 10 26
Sites of metastasis at metastatic diagnosis
Bone 25 62
Liver 12 30
Lung 5 12
Chemotherapy
Paclitaxel 31 78
Docetaxel 4 10
Nab-paclitaxel 5 12
Biological therapy
Trastuzumab 11 27
Pertuzumab/Trastuzumab 4 10
Bevacizumab 10 25
Chemotherapy
Paclitaxel 31 78
Docetaxel 4 10
Nab-paclitaxel 5 12
Body composition measures
Sarcopenia 23 (58)
Skeletal Muscle Index (cm2/m2) 41.2 (9.1)
Skeletal Muscle Density (Hounsfield Units) 29.8 (10)
Skeletal Muscle Gauge (Arbitrary Units) 1249 (522)
Body Mass Index (kg/m2) 29.0 (7.3)
Body Surface Area (m2) 1.87 (0.26)
Lean Body Massa (kg) 39.3 (7.2)
Toxicity eventsb
All grade 3–4 Cycles 1–3 16 40
 Grade 3–4 neutropenia 7 17.5
 Grade 3–4 anemia 3 7.5
 Grade 3–4 gastrointestinal toxicity 5 12.5
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N/mean (SD) %
 Grade 3–4 neuropathy 6 15
 Grade 3–4 neutropenic fever 2 5
Hospitalizations
All hospitalizations 9 23
 Infection 5 13
 Gastrointestinal toxicity 2 5
 Neutropenic fever 2 5
Dose reductions 10 25
Dose delays 11 28
Any adverse eventc 23 58
a
Estimated Lean Body Mass(7);
bGrade 3–4 toxicity by CTCAE(11) in cycles 1–3 of chemotherapy;
cAny adverse event includes hospitalization, grade 3–4 toxicity, dose reductions, or delay
Abbreviations: HR- hormone receptor; HER2- human epidermal growth factor Receptor 2; SD- standard deviation
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